A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Public ClinicalTrials.gov record NCT06557265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Autoimmune Disease
Study identification
- NCT ID
- NCT06557265
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Nkarta, Inc.
- Industry
- Enrollment
- 96 participants
Conditions and interventions
Conditions
Interventions
- Fludarabine, Cyclophosphamide Drug
- NKX019 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2024
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
- Last update posted
- Mar 8, 2026
2024 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nkarta Investigational Site | Little Rock | Arkansas | 72201 | Recruiting |
| Nkarta Investigational Site | Gainesville | Florida | 32610 | Recruiting |
| Nkarta Investigational Site | Miami | Florida | 33133 | Withdrawn |
| Nkarta Investigational Site | Plantation | Florida | 33317 | Recruiting |
| Nkarta Investigational Site | Tampa | Florida | 33602 | Recruiting |
| Nkarta Investigational Site | Atlanta | Georgia | 30303 | Recruiting |
| Nkarta Investigational Site | Chicago | Illinois | 60612 | Recruiting |
| Nkarta Investigational Site | New Orleans | Louisiana | 70112 | Recruiting |
| Nkarta Investigational Site | Worcester | Massachusetts | 01608 | Recruiting |
| Nkarta Investigational Site | Ann Arbor | Michigan | 48109 | Recruiting |
| Nkarta Investigational Site | New York | New York | 10007 | Recruiting |
| Nkarta Investigational Site | Stony Brook | New York | 11794 | Recruiting |
| Nkarta Investigational Site | Syracuse | New York | 13202 | Recruiting |
| Nkarta Investigational Site | Dallas | Texas | 75201 | Recruiting |
| Nkarta Investigational Site | Houston | Texas | 77002 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06557265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06557265 live on ClinicalTrials.gov.